Paroxysmal extreme pain disorder

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Retrieved on: 
Wednesday, June 21, 2023

This approach systematically generates promising small molecule drug candidates at unprecedented speed.

Key Points: 
  • This approach systematically generates promising small molecule drug candidates at unprecedented speed.
  • Founded by Flagship Pioneering, Empress generates good medicines, fast by starting with chemistry inside the human body.
  • Flagship has made an initial commitment of $50 million to support the development of Empress's platform and the company's initial pipeline of drug candidates.
  • In much the same way, we can now apply the programmability of the DNA code to create small molecule drugs predictably and quickly."

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

Retrieved on: 
Wednesday, October 20, 2021

"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.

Key Points: 
  • "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
  • RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
  • The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
  • Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.

Confluent Health Welcomes Manual Edge Physiotherapy to its Growing Network of Private Practices

Retrieved on: 
Monday, August 30, 2021

LOUISVILLE, Ky., Aug. 30, 2021 /PRNewswire-PRWeb/ -- Confluent Health has announced its newest partnership with Manual Edge Physiotherapy (Manual Edge PT), a private and therapist-owned physical therapy practice located in Colorado Springs, Colorado.

Key Points: 
  • LOUISVILLE, Ky., Aug. 30, 2021 /PRNewswire-PRWeb/ -- Confluent Health has announced its newest partnership with Manual Edge Physiotherapy (Manual Edge PT), a private and therapist-owned physical therapy practice located in Colorado Springs, Colorado.
  • This partnership allows for Manual Edge PT to maintain its existing brand while gaining access to Confluent Health's shared management services.
  • "We've known about Manual Edge PT and their dedication to individualized and personal care for years," says Confluent Health's President and CEO Larry Benz, PT, DPT, OCS, MBA, MAPP.
  • Manual Edge Physiotherapy (Manual Edge PT) is a Colorado-based, private physical therapy practice group.

Navega Therapeutics expands its Scientific Advisory Board with the addition of pain expert, Dr. Stephen Waxman.

Retrieved on: 
Tuesday, August 24, 2021

One and a half billion people worldwide suffer from chronic pain, with more than 100 million in the US alone.

Key Points: 
  • One and a half billion people worldwide suffer from chronic pain, with more than 100 million in the US alone.
  • Navega Therapeutics is pursuing a radically different approach based on DNA targeting to treat chronic pain and tackle the opioid epidemic via epigenetic regulation of key genes.
  • About Navega Therapeutics Inc. | Navega is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common disease.
  • The same pharmaceutical product will be utilized to reduce chronic pain in other pain disorders.